causal
Oligonucleotide Production Is Hard To Replicate At Scale
Agilent has no competitor with equal or larger capacity for producing specialist oligonucleotides at production grade, so small quantities are easy to make but commercial volumes for vaccines and drugs effectively only Agilent can supply, and it works with all the main manufacturers of these drugs.
causalpending
Speaker
MarcEvidence Quote
“But if you want to make production-grade stuff where you can make 100,000 vaccines, then really it's only Agilent you can work with who have that facility.”
Created: 11/12/2026, 11:55:35 AM
Your notes
Loading notes...